TWP
REGN icon

TFO Wealth Partners’s Regeneron Pharmaceuticals REGN Stock Holding History

TFO Wealth Partners’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1
Closed -$962 – 602
2024
Q1 		$962 Hold
1
– – ﹤0.01% 168
2023
Q4 		$878 Sell
1
-1
-50% -$823 ﹤0.01% 222
2023
Q3 		$1.44K Buy
2
+1
+100% +$786 ﹤0.01% 230
2023
Q2 		$719 Hold
1
– – ﹤0.01% 234
2023
Q1 		$822 Sell
1
-8
-89% -$6.03K ﹤0.01% 187
2022
Q4 		$908 Buy
+9
New +$6.64K ﹤0.01% 388
2022
Q3 		– Sell
-8
Closed -$5K – 412
2022
Q2 		$5K Buy
+8
New +$5.2K ﹤0.01% 214

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

TFO Wealth Partners's REGN Position: Q2 2024 in Review

TFO Wealth Partners sold out of Regeneron Pharmaceuticals (REGN) in Q2 2024, closing a stake of 1 share — an estimated $962 sold.

TFO Wealth Partners first reported a position in REGN in Q2 2022 and held it in 7 quarters. The position peaked at $5K in Q2 2022. 1,334 funds tracked by Wall St. Rank hold REGN as of Q2 2024.

  • TFO Wealth Partners reported no remaining Regeneron Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • TFO Wealth Partners sold 1 Regeneron Pharmaceuticals share in Q2 2024, an estimated $962.
  • TFO Wealth Partners first reported a position in Regeneron Pharmaceuticals in Q2 2022 and held it in 7 quarters.
  • TFO Wealth Partners's Regeneron Pharmaceuticals position peaked at $5K in Q2 2022.
  • 1,334 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2024.

Based on TFO Wealth Partners's 13F filing for Q2 2024, filed 15 Aug 2024.